Baird Medical Investment signs US$ 4.35 million senior OID convertible note deal with institutional investor

• Baird Medical entered a Securities Purchase Agreement on Sept. 24, 2026 with an institutional investor for a senior 8% OID convertible promissory note.
• Issued a US$4,347,826 note with a 12-month term; no interest unless default triggers 15% annual interest, compounding monthly.
• Added a 2% OID, issuing 110,070 ordinary shares priced at US$0.79 as discount shares.
• Conversion price set at the lower of US$0.9842 or 92% of the lowest seven-day VWAP, subject to a floor price.
• Investor received first-priority security over U.S. subsidiary equity and substantially all U.S.-located assets; subsidiaries provided guarantees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baird Medical Investment Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-112324), on September 30, 2026, and is solely responsible for the information contained therein.